Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Oda Y, Kumagai Y, Kanai M, Iwama Y, Okura I, Minamida T, Yagi Y, Kurosawa T, Greener B, Zhang Y, Walson JL. Oda Y, et al. Among authors: minamida t. Lancet Infect Dis. 2024 Apr;24(4):351-360. doi: 10.1016/S1473-3099(23)00650-3. Epub 2023 Dec 20. Lancet Infect Dis. 2024. PMID: 38141632 Clinical Trial.
Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial.
Okada Y, Kumagai Y, Okura I, Otsuki M, Ishida N, Iwama Y, Minamida T, Yagi Y, Kurosawa T, van Boxmeer J, Zhang Y, Smolenov I, Walson JL. Okada Y, et al. Among authors: minamida t. Lancet Infect Dis. 2024 Oct 23:S1473-3099(24)00565-6. doi: 10.1016/S1473-3099(24)00565-6. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39461355
Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study.
Sugimoto T, Shiraki M, Fukunaga M, Kishimoto H, Hagino H, Sone T, Nakano T, Ito M, Yoshikawa H, Minamida T, Tsuruya Y, Nakamura T. Sugimoto T, et al. Among authors: minamida t. Osteoporos Int. 2019 Nov;30(11):2321-2331. doi: 10.1007/s00198-019-05111-6. Epub 2019 Aug 8. Osteoporos Int. 2019. PMID: 31392401 Free PMC article. Clinical Trial.